Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 801–900 of 1,000
Mausner-Fainberg, K., Penn, M., Golan, M., Benhamou, M., Wilf‐Yarkoni, A., Gertel, S., & Karni, A. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.01.009 · Cited by 3
Transplantation myelinbildender Zellen als regenerative Therapie bei Multipler Sklerose
Stangel, M. (2002) · Der Nervenarzt · doi:10.1007/s00115-002-1370-8 · Cited by 3
“Sollte die Ursache der mangelhaften Remyelinisierung von MS-Plaques darin liegen, dass die Axone für eine Remyelinisierung nicht rezeptiv sind [23], so stellt sich das prinzipielle Problem, ob durch die Zelltransplantation eine Remyelinisierung überhaupt möglich ist.”
BackgroundInfluentialMULTIPLE SCLEROSIS: REMYELINATION
Kocsis, J. D., Sasaki, M., Lankford, K. L., & Radtke, C. (2008) · Elsevier eBooks · doi:10.1016/b978-012373994-0.50020-8 · Cited by 3
Dissertation zur Erlangung des Grades
der Naturwissenschaften, D., Osnabrück, U., Bröcker, C., & März, O. (2014) · Cited by 3
Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination
Loo, H. K., Gallegos, J., Mialki, C., Perrin, G. E., Malloy, T., & Orthmann‐Murphy, J. L. (2026) · Glia · doi:10.1002/glia.70120 · Cited by 4
“The long-term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
Illés, Z., Lassmann, H., & Gallyas, F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_15 · Cited by 2
G Protein‐Coupled Receptor Signaling in CNS (Re)Myelination
McDonald, J. K., Ang, S. Y., Langmead, C. J., & Stewart, G. D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70286 · Cited by 2
Li, D., Dai, W., Li, L., Zhou, Z., Li, Z., He, C., Li, X., Lu, X., Huang, Q., Zhu, Y., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.01.013 · Cited by 3
Glial D-serine modulates oligodendrocyte lineage progression under inflammatory conditions
Espinoza, J. P., Cisterna, I., Triviño, J. J., Arancibia, V., & Beltrán-Castillo, S. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1784678 · Cited by 2
Therapeutic ultrasound for the treatment of demyelinating diseases
Micali, M., Toschi, N., & Conti, A. (2026) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2026.102913 · Cited by 3
Yu, Q., Xiong, J., Cai, J., Zhang, Z., Ma, L., Yu, Y., Huang, M., Zhang, Y., & Ye, S. Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116718 · Cited by 2
Kira, J., & Isobe, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_15 · Cited by 2
Sanner, A., Hardt, R., Matzner, U., & Winter, D. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04378 · Cited by 2
Exogenous Cell Myelin Repair and Neuroprotection in Multiple Sclerosis
Duncan, I. D., & Kondo, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2218-1_5 · Cited by 2
Fressinaud, C. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90420-8 · Cited by 2
Multiple Sclerosis and Autoimmune Encephalomyelitis
Lassmann, H. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_18 · Cited by 3
Wekerle, H., & Meinl, E. (2013) · Nature · doi:10.1038/nature12694 · Cited by 2
Neuroinflammation in Neurological Disorders
Kira, J. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_2 · Cited by 3
Neuroimmunologic Mechanisms in the Etiology of Multiple Sclerosis
Lucchinetti, C. F., Brück, W., & Lassmann, H. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_19 · Cited by 2
Future Therapies for Progressive Multiple Sclerosis
Scolding, N. J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2395-8_10 · Cited by 2
Wilczak, N., Keyser, J. D., & Chesik, D. (2008) · Drug Target Insights · doi:10.4137/dti.s362 · Cited by 2
“Most chronic lesions of MS demonstrate no remyelination, although oligodendrocyte precursor cells and premyelinating oligodendrocytes are present in many demyelinated plaques (Chang et al. 2002; Scolding et al. 1998; Wolswijk, 2002).”
BackgroundNeurodegenerative Mechanisms of Multiple Sclerosis
Xu, H. (2014) · Cited by 2
Remyelination in Multiple Sclerosis – How Close are We?
Palavraa, L. A. F. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000192 · Cited by 4
Oligodendrocyte Progenitor Cell Cultures: A Model to Screen Neurotrophic Compounds for Myelin Repair
Barbierato, M., Skaper, S. D., & Facci, L. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7571-6_12 · Cited by 2
Responses of the SVZ to Demyelinating Diseases
Nait‐Oumesmar, B., Decker, L., Picard-Riéra, N., & Evercooren, A. B. (2006) · Springer eBooks · doi:10.1007/0-387-31389-3_9 · Cited by 2
“Further investigation should determine whether PSA-NCAMþ cells in the lesions originate from the SVZ and if these cells are more likely to proliferate and differentiate in myelin-competent cells than the oligodendrocyte progenitors recently identified in MS lesions ( Chang et al., 2002; Wolswijk, 2000).”
BackgroundThe best basic science paper in MS in 2013: Antimuscarinic therapies in remyelination
Green, A. (2014) · Multiple Sclerosis · doi:10.1177/1352458514558679 · Cited by 1
Zhu, F., Huang, H., Shu, Y., Ren, G., Jing, B., Tan, H., Jiang, W., Cui, Y., Worley, P. F., Xiao, B., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07996-0 · Cited by 1
“In MS lesions, the OPCs exist in the areas surrounding demyelinated lesions (albeit in reduced numbers in some cases), but they somehow fail to mature to oligodendrocytes capable of producing myelin [11, 12].”
Peters, A., Yasuhara, K., Su, W., Matsumoto, S. G., Pham, P. T., Banine, F., Harris, E., Back, S. A., & Sherman, L. S. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2600157 · Cited by 2
“Remyelination failure is linked, at least in part, to the inability of oligodendrocyte progenitor cells (OPCs) at lesion sites to mature into myelinating oligo-dendrocytes (OLs) (Chang et al., 2002; Maeda et al., 2001; Scolding et al., 1998; Wolswijk, 1998).”
Shao, Q., Li, Z., Tan, W., Pu, Y., Sun, D., FANG, X., Shi, X., Zhang, X., Liu, W., Liu, M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adu6987 · Cited by 1
Narayanan, S., Caramanos, Z., Matthews, P. M., & Arnold, D. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.015 · Cited by 1
Emerging Strategies For the Treatment of Multiple Sclerosis
Sand, I. K., & Krieger, S. C. (2012) · Future Neurology · doi:10.2217/fnl.12.9 · Cited by 1
Bradl, M., & Lassmann, H. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199794591.003.0061 · Cited by 1
Fox, R. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00139-9 · Cited by 1
Macrophages and Microglia in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Mishra, M. K., & Yong, V. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_9 · Cited by 1
Pourabdolhossein, F., Mozafari, S., Javan, M., Mirnajafi‐Zadeh, J., & Ahmadiani, A. (2011) · Cited by 1
Neural Stem Cells and Demyelinating Disease
Crawford, A. H., & Franklin, R. J. M. (2014) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-1908-6_8 · Cited by 1
Multiple Sclerosis: Etiology and Mechanism, with Special Reference to Asians
Kira, J. (2016) · Springer eBooks · doi:10.1007/978-4-431-55594-0_5 · Cited by 1
Kilpatrick, T. J., Ransohoff, R. M., & Wesselingh, S. L. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9781139195805.006 · Cited by 1
Șair ve Hekim Aḥmedī’nin Tervīḥü’l-Ervāḥ adlı manzum eserinde“geriatri” üzerine bir bölüm
Ahmet, A. (2016) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.1501/tipfak_0000000921 · Cited by 1
Interactions between Axon Cytoskeleton Proteins and Oligodendrocytes during Remyelination
Fressinaud, C. (2016) · doi:10.24947/baojn/2/1/114 · Cited by 1
“Finally, as numerous OL at a premyelinating stage have been observed in contact with dystrophic axons, it has been hypothesized that axons might be improper for remyelination [20].”
BackgroundCohen, J. A., & Rae-Grant, A. D. (2012) · doi:10.1007/978-1-907673-50-4_1 · Cited by 1
Fishing for a balance: Toward promyelinating drug discovery
Collins, H. Y., & Emery, B. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.09.005 · Cited by 1
Neuroglial components of brain lesions may provide new therapeutic strategies for multiple sclerosis
Khanghahi, A. M., Rayatpour, A., Baharvand, H., & Javan, M. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06915-5 · Cited by 1
Liampas, A., Tseriotis, V., Artemiadis, A., Zis, P., Argyropoulou, C., Grigoriadis, N., Hadjigeorgiou, G. M., & Vavougyios, G. D. (2024) · Brain Connectivity · doi:10.1089/brain.2023.0081 · Cited by 1
“…Starossom et al., 2011; Tepav (cid:2) cevi ć et al., 2011; Wang et al., 2008), brain tissues of patients with MS in fi ve studies (Chang et al., 2008; Chang et al., 2002; Nait-Oumesmar et al., 2007; Oreja-Guevara et al., 2017; Petratos et al., 2004), animal models with EAE and brain tissues of…”
InfluentialThe use of immunomodulators in multiple sclerosis: diagnosis, treatment and neurological examination
Malaquias, D. T. M., Vivas, A. D., Paschoal, J. F. B., Prezotto, E. F., Carvalho, J. V., Garcia, F. J. L., Parreira, A. C. F., de Souza, V. H., Alineri, T. P. M., Silva, K. D. N., et al. (2024) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2024.14.00584 · Cited by 2
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
Kroner, A., Kleinschnitz, C., Stadelmann, C., Raab, P., Stangel, M., Trebst, C., Voß, E. V., & Cordes, A.-L. (2011) · Springer eBooks · doi:10.1007/978-3-642-20477-7_1 · Cited by 4
Versijpt, J. J. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
Gold, R. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.015 · Cited by 1
Evercooren, A. B., Lachapelle, F., Nait‐Oumesmar, B., & Pham-Dinh, D. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90459-2 · Cited by 1
La SEP, maladie inflammatoire ou maladie dégénérative ?
Confavreux, C., & Vukusic, S. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)98510-7 · Cited by 1
Cell Transplantation for Diseases of Myelin
Ben‐Hur, T., & Einstein, O. (2006) · Springer eBooks · doi:10.1007/1-84628-142-3_6 · Cited by 1
Schädigungs- und Reparaturmechanismen in Multiple-Sklerose-Läsionen
Kuhlmann, T. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1628689 · Cited by 1
“nicht zu myelinisierenden Zellen heran (16, 32, 61, 62) ( Abb.”
BackgroundMultiple Sklerose: potenzielle Therapieansätze und Update laufender Studien
Wiendl, H., Lehmann, H. C., Hohlfeld, R., Hartung, H., & Kieseier, B. C. (2004) · Der Nervenarzt · doi:10.1007/s00115-003-1665-4 · Cited by 6
Opportunities and Challenges of the Therapies Targeting CNS Regeneration
Perez, H. D., Mitrovic, B., & Evercooren, A. B. (2005) · Springer eBooks · doi:10.1007/3-540-27626-2 · Cited by 1
“However, in manyMS plaques oligodendrocyte progenitors are present, which remain in an undifferentiated stage and fail to remyelinate (Chang et al. 2002).”
BackgroundInfluentialIdentification of a unique oligodendrocyte subpopulation in mouse brain
Khojasteh-Fard, M. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7076 · Cited by 1
Ding, Z., Han, Q.-X., Song, L., Wang, Q., Han, G., Chu, G.-G., Li, Y., Chai, Z., Yu, J., Xiao, B., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-531893/v1 · Cited by 1
“In progressive MS patients, although OPCs are present in the demyelinating lesion, mature OLs are almost completely de cient (Chang et al. 2002; Kuhlmann et al. 2008).”
BackgroundLyons, D. A., & Almeida, R. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732872241.793545529 · Cited by 1
Beyer, B. A., Sul, A., Miller, J., Neumann, B., Plaisted, W. C., Kondo, T., Franklin, R. J. M., & Lairson, L. L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.11.548469 · Cited by 1
The role of hypoxia in neuroinflammatory disease
Desai, R. (2013) · UCL Discovery (University College London) · Cited by 1
Pre-myelinating oligodendrocyte ADGRG1 is required for axon ensheathment and CNS myelin formationPreprint
Zhu, B., Li, T., Rodrigues, B. V., Piller, M., Call, C. L., Mogha, A., Belloso-Iguerategui, A., Chiou, B., Schmidt, R., Wangzhou, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.26.701898 · Cited by 1
Premyelinating Oligodendrocyte Survival Governs CNS RemyelinationPreprint
Stockton, M. E., Wentling, M., Corchado, Y. I. M., Kucera, A. J., Karas, S., Seabrook, T. A., Mutschler, C., Osso, L. A., Schuster, K. H., Nunes, G. D. F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707571 · Cited by 2
“In human multiple sclerosis (MS) lesions, OPCs are commonly present 22,23 , and can differentiate into preOLs 17,24 .”
Sanson, C. (2017) · theses.fr (ABES) · doi:10.70675/205f3741zaac1z422eza6aeza2902010260f · Cited by 1
Die Rolle der Beta-Sekretase bei der Myelinisierung im Zentralen Nervensystem
Treiber, H. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4444
The cuprizone model and multiple sclerosis : disparities and similarities
Kipp, M., & Baumgärtner, W. (2011) · RWTH Publications (RWTH Aachen) · Cited by 1
Biochemical analysis of the basic helix-loop-helix transcription factor Olig2
Meijer, D. H. (2014) · Utrecht University Repository (Utrecht University)
Jürgens, T. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3904
The role of complement anaphylatoxins in CNS pathology and glial cell function
Ingersoll, S. A. (2010) · doi:10.17077/etd.k0bgyd8z
Multipl Sklerozu Düşündüren Atipik Demiyelinizan Hastalıklar
Koçer, A., Gözke, E., Öre, Ö., & Us, Ö. (2004) · DergiPark (Istanbul University)
Ohta, K., Iwai, M., Sato, K., Omori, N., Nagano, I., Shoji, M., & Abe, K. (2003) · International Congress Series · doi:10.1016/s0531-5131(03)00068-2
Amelioration of experimental allergic encephalomyelitis (eae) by phase 2 enzyme inducer
Yunus, M. (2010) · University Library - University of Saskatchewan (University of Saskatchewan)
Neuron–Oligodendrocyte Interactions in Neuroinflammation
Ikenaka, K. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_6
Multiple Sklerose und verwandte Erkrankungen
Kuhlmann, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-02324-8_13 · Cited by 2
“Mitursächlich für diese letztendlich unzureichende Remyelinisierung scheint ein Differenzierungsblock der oligodendroglialen Vorläuferzellen zu sein, der vor allen in chronischen Läsionstadien beobachtet wird [10, 24, 37].”
BackgroundMuñoz-Sanjuán, I. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903443105
“However, in the case of MS, there is evidence to suggest that the inability to induce remyelination is not due to a loss of GPCs, but rather in the interactions between oligodendrocytes and axons to facilitate this process [33-35].”
Background(2015) · Therapeutic Targets for Neurological Diseases · doi:10.14800/ttnd.409
“Similarly, an affection of OPC differentiation has been proposed for multiple sclerosis (MS), an autoimmune disease directed against myelin components with severe focal demyelination [19, 20] .”
BackgroundPutative effects of neurofilaments released during multiple sclerosis
Fressinaud, C. (2020) · doi:10.5348/n06-2015-4-ed-3
“In MS lesions the presence of OL in contact with axons, and lacking proper differentiation in order to undertake their remyelination [11], suggests that signal from damaged axons is inappropriate to trigger remyelination.”
BackgroundBelachew, S. M. (2005) · ORBi (University of Liège)
(2010) · Multiple Sclerosis Journal · doi:10.1177/13524585100160081301
Charakterisierung der subzellulären Lokalisation von Myelinproteinen in der Shiverer-Maus.
Winter, C. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-814
Endogenous Mechanisms of Neuroprotection and Neuroregeneration
Montalbán, X. (2005) · Rivista di Neuroradiologia · doi:10.1177/197140090501800408
ADVANCES IN THE NEUROPATHOLOGY OF MULTIPLE SCLEROSIS: EVOLVING PATHOGENIC INSIGHTS
Lucchinetti, C. F. (2007) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000293642.36235.75
“…1998) suggests that the failure of remyelination during these late disease phases may be due to an absence of factors leading to their differentiation into mature oligodendrocytes or a defect in axons rendering them not receptive to myelination signals (Chang et al, 2002; Charles et al, 2002).”
BackgroundNeuron-Oligodendrocyte Co-culture Device for Measuring Action Potential Conduction Velocity
Sakai, K., Shimba, K., Arimatsu, K., Kotani, K., & Jimbo, Y. (2014) · IEEJ Transactions on Electronics Information and Systems · doi:10.1541/ieejeiss.134.1056
(Stem) Cell Based Therapy for Neurological Disorders
Einstein, O., & Ben‐Hur, T. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732246-00203
Le phénomène de remyélinisation dans la sclérose en plaques
Lubetzki, C. (2003) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)34000-2 · Cited by 1
SVEUČILIŠTE U ZAGREBU MEDICINSKI FAKULTET
Krajcar, N. (2014)
Biologic Therapies For Multiple Sclerosis
da Fontoura, P. P., & Garren, H. (2009) · CRC Press eBooks · doi:10.1201/9781420063219.sec2
Pathologie und Pathophysiologie
Stadelmann, C., & Brück, W. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22083-8.00004-3 · Cited by 1
Noble, M., Mayer-Pröschel, M., Mock, D. J., & Pröschel, C. (2005) · CRC Press eBooks · doi:10.1201/9781420039849.ch5
Remyelination in the Central Nervous System
(1989) · KARGER eBooks · doi:10.1159/isbn.978-3-8055-8766-2 · Cited by 3
The oligodendrocyte "processosome": novel regulators of differentiation and myelination
da Silva, A. F. B. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/1zbe-vq61
Clarner, T., & Beyer, C. (2011) · RWTH Publications (RWTH Aachen)
microRNAs in Oligodendrocyte Myelination and Repair in the Central Nervous System
Zhao, X., Wang, H., & Lu, Q. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804402-5.00011-x
Stereological Analysis of Oligodendrocyte Progenitor Cells In the Adult Mouse Brain
Boulanger, J. J. (2017) · uO Research (University of Ottawa) · doi:10.20381/ruor-20632
Felipe, A. (2016) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2016/5.1034
Eicosapentaenoic Acid in Myelinogenesis
Biase, A. D., Attorri, L., Benedetto, R. D., & Salvati, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805298-3.00027-x
On the role of macrophages, microglia and the extracellular matrix in remyelination
Wang, P. (2018) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.